InnoCare Says Orelabrutinib Phase III ITP Study Met Primary Endpoint
InnoCare announced Phase III results for orelabrutinib in an ITP study, saying the trial met its primary endpoint.
Story updates
10:37:03 AM UTC
SquawkNews
InnoCare's Phase III orelabrutinib study in chronic ITP met its primary endpoint, with a 32.8% durable response rate, 25.5% higher than placebo (P=0.0001). China's NDA acceptance for orelabrutinib in ITP was also announced.Material DetailsContext by AI AnalystThis is a late-stage clinical and regul…